Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KMDA NASDAQ:QURE NASDAQ:RXRX NASDAQ:TYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKMDAKamada$7.31$7.94$6.50▼$9.35$420.40M0.8342,911 shs25,147 shsQUREuniQure$46.29$24.13$8.73▼$71.50$2.92B0.982.20 million shs4.85 million shsRXRXRecursion Pharmaceuticals$3.23$3.32$2.77▼$7.18$1.71B1.0421.03 million shs24.75 million shsTYRATyra Biosciences$28.32$32.85$8.98▼$40.65$1.68B0.75838,075 shs2.53 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKMDAKamada+0.69%-1.75%-3.82%-14.00%+1.25%QUREuniQure-3.88%+72.60%+87.48%+187.69%+206.56%RXRXRecursion Pharmaceuticals+3.86%+2.54%+13.33%-0.62%-36.79%TYRATyra Biosciences-2.58%+10.75%-16.16%-23.77%+198.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKMDAKamada$7.31$7.94$6.50▼$9.35$420.40M0.8342,911 shs25,147 shsQUREuniQure$46.29$24.13$8.73▼$71.50$2.92B0.982.20 million shs4.85 million shsRXRXRecursion Pharmaceuticals$3.23$3.32$2.77▼$7.18$1.71B1.0421.03 million shs24.75 million shsTYRATyra Biosciences$28.32$32.85$8.98▼$40.65$1.68B0.75838,075 shs2.53 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKMDAKamada+0.69%-1.75%-3.82%-14.00%+1.25%QUREuniQure-3.88%+72.60%+87.48%+187.69%+206.56%RXRXRecursion Pharmaceuticals+3.86%+2.54%+13.33%-0.62%-36.79%TYRATyra Biosciences-2.58%+10.75%-16.16%-23.77%+198.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKMDAKamada 3.00Buy$12.0064.16% UpsideQUREuniQure 2.65Moderate Buy$58.9227.28% UpsideRXRXRecursion Pharmaceuticals 2.20Hold$8.10150.77% UpsideTYRATyra Biosciences 2.87Moderate Buy$47.0065.96% UpsideCurrent Analyst Ratings BreakdownLatest KMDA, QURE, TYRA, and RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026QUREuniQure Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$35.00 ➝ $65.006/18/2026QUREuniQure HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/18/2026QUREuniQure Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $70.006/18/2026QUREuniQure The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$14.00 ➝ $46.006/18/2026QUREuniQure BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$25.00 ➝ $65.006/17/2026QUREuniQure BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingPositive6/17/2026QUREuniQure Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight$61.006/17/2026TYRATyra Biosciences JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$56.006/10/2026TYRATyra Biosciences Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$37.00 ➝ $42.005/19/2026TYRATyra Biosciences Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoveragePeer Perform5/15/2026KMDAKamada Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKMDAKamada$180.46M2.33$0.61 per share11.89$4.68 per share1.56QUREuniQure$16.10M181.34N/AN/A$3.19 per share14.51RXRXRecursion Pharmaceuticals$74.68M22.92N/AN/A$2.14 per share1.51TYRATyra BiosciencesN/AN/AN/AN/A$4.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKMDAKamada$20.20M$0.3520.8911.980.6711.21%7.73%5.41%8/12/2026 (Estimated)QUREuniQure-$198.97M-$3.48N/AN/AN/A-1,154.42%-145.81%-27.15%8/4/2026 (Estimated)RXRXRecursion Pharmaceuticals-$644.76M-$1.20N/AN/AN/A-842.95%-54.33%-40.60%8/4/2026 (Estimated)TYRATyra Biosciences-$119.95M-$2.18N/AN/AN/AN/A-42.66%-39.79%8/13/2026 (Estimated)Latest KMDA, QURE, TYRA, and RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026KMDAKamada$0.12$0.07-$0.05$0.07$46.72 million$45.24 million5/13/2026Q1 2026TYRATyra Biosciences-$0.60-$0.64-$0.04-$0.64N/AN/A5/6/2026Q1 2026RXRXRecursion Pharmaceuticals-$0.30-$0.22+$0.08-$0.22$15.78 million$6.47 million5/5/2026Q1 2026QUREuniQure-$0.88-$0.85+$0.03-$0.85$5.21 million$3.56 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKMDAKamada$0.192.60%N/A54.29%N/AQUREuniQureN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKMDAKamadaN/A3.331.90QUREuniQure0.3310.4010.40RXRXRecursion Pharmaceuticals0.015.475.47TYRATyra BiosciencesN/A20.4920.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKMDAKamada20.38%QUREuniQure78.83%RXRXRecursion Pharmaceuticals89.06%TYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipKMDAKamada36.10%QUREuniQure4.65%RXRXRecursion Pharmaceuticals6.65%TYRATyra Biosciences12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKMDAKamada36057.51 million36.75 millionOptionableQUREuniQure50063.07 million60.13 millionOptionableRXRXRecursion Pharmaceuticals400529.91 million494.67 millionOptionableTYRATyra Biosciences2059.47 million52.04 millionOptionableKMDA, QURE, TYRA, and RXRX HeadlinesRecent News About These Companies5AM Venture Management LLC Buys 90,000 Shares of Tyra Biosciences, Inc. $TYRAJune 18 at 3:06 AM | marketbeat.comFinancial Survey: Tyra Biosciences (NASDAQ:TYRA) versus Belite Bio (NASDAQ:BLTE)June 17 at 4:49 AM | americanbankingnews.comTyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 16 at 2:19 AM | americanbankingnews.comIs Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism?June 12, 2026 | finance.yahoo.comWolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)June 1, 2026 | finance.yahoo.comWolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)June 1, 2026 | insidermonkey.comTYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAYMay 21, 2026 | prnewswire.comWolfe Research initiates coverage of Tyra Biosciences (TYRA) with peer perform recommendationMay 20, 2026 | msn.comTyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More SharesMay 17, 2026 | fool.comAssessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price MomentumMay 15, 2026 | finance.yahoo.comHot Picks: Cancer biotech stocks gain ground amid M&A activityMay 13, 2026 | bnnbloomberg.caBTyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comTyra Biosciences Reports First Quarter 2026 Financial Results and Recent HighlightsMay 13, 2026 | prnewswire.comTyra Biosciences to Participate in Upcoming Investor ConferencesMay 7, 2026 | prnewswire.comTyra Biosciences faces earnings test ahead of key trial dataApril 29, 2026 | investing.comTyra Bioscience, IncApril 25, 2026 | edition.cnn.comTyra Bioscience (TYRA) Receives a Buy from OppenheimerApril 25, 2026 | theglobeandmail.comGuggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug DabogratinibApril 24, 2026 | insidermonkey.comTyra Biosciences, Inc. ($TYRA) CEO 2025 Pay RevealedApril 17, 2026 | quiverquant.comQTyra Biosciences Announces Appointment of Habib Dable to its Board of DirectorsApril 17, 2026 | prnewswire.comGuggenheim initiates coverage of Tyra Biosciences (TYRA) with buy recommendationApril 16, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKMDA, QURE, TYRA, and RXRX Company DescriptionsKamada NASDAQ:KMDA$7.31 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$7.31 0.00 (0.00%) As of 06/18/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.uniQure NASDAQ:QURE$46.29 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$46.52 +0.23 (+0.50%) As of 06/18/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Recursion Pharmaceuticals NASDAQ:RXRX$3.23 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$3.19 -0.04 (-1.21%) As of 06/18/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Tyra Biosciences NASDAQ:TYRA$28.32 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$28.32 0.00 (-0.02%) As of 06/18/2026 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate American Eagle’s Q1 Beat Leaves Investors With a Bigger Question Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
